Assertio Holdings Inc (ASRT)
0.8154
+0.03
(+3.86%)
USD |
NASDAQ |
Apr 26, 10:57
Assertio Holdings Research and Development Expense (Quarterly): 1.024M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.024M |
| September 30, 2023 | 1.316M |
| June 30, 2023 | 0.503M |
| March 31, 2023 | |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.23M |
| September 30, 2020 | 1.316M |
| June 30, 2020 | 1.626M |
| March 31, 2020 | 1.041M |
| December 31, 2019 | 5.575M |
| September 30, 2019 | 1.476M |
| June 30, 2019 | 1.263M |
| March 31, 2019 | 1.793M |
| December 31, 2018 | 2.207M |
| September 30, 2018 | 2.127M |
| June 30, 2018 | 2.18M |
| March 31, 2018 | 1.528M |
| December 31, 2017 | 26.16M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.761M |
| June 30, 2017 | 5.614M |
| March 31, 2017 | 5.084M |
| December 31, 2016 | 9.154M |
| September 30, 2016 | 10.41M |
| June 30, 2016 | 7.116M |
| March 31, 2016 | 5.949M |
| December 31, 2015 | 61.24M |
| September 30, 2015 | 4.629M |
| June 30, 2015 | 4.714M |
| March 31, 2015 | 1.858M |
| December 31, 2014 | 2.033M |
| September 30, 2014 | 1.644M |
| June 30, 2014 | 1.397M |
| March 31, 2014 | 2.042M |
| December 31, 2013 | 2.024M |
| September 30, 2013 | 1.339M |
| June 30, 2013 | 1.412M |
| March 31, 2013 | 3.298M |
| December 31, 2012 | 3.185M |
| September 30, 2012 | 5.27M |
| June 30, 2012 | 3.525M |
| March 31, 2012 | 3.482M |
| December 31, 2011 | 2.782M |
| September 30, 2011 | 3.208M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2022
5.575M
Maximum
Dec 2019
1.182M
Average
1.041M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| Ocular Therapeutix Inc | 16.20M |
| Cormedix Inc | 2.289M |
| Verastem Inc | 22.50M |
| Puma Biotechnology Inc | 12.87M |
| BioVie Inc | 6.470M |